Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00461136
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00441064
- Locations
- 🇺🇸
Novartis US, Madison, Wisconsin, United States
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00417170
- Locations
- 🇺🇸
Novartis Investigative Site, Santa Monica, California, United States
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416728
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416468
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 820
- Registration Number
- NCT00414609
- Locations
- 🇮🇳
Novartis Healthcare Private Limited, Worli, Mumbai, India
🇵🇱Novartis Poland Sp. z o.o., Warszawa, Poland
🇭🇺Novartis Hungary, Budapest, Hungary
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00402103
- Locations
- 🇩🇪
Investigative Center, Investigative Center, Germany
🇧🇪Investigator Site, Investigative Site, Belgium
🇨🇭Investigative Site, Investigative Site, Switzerland
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 601
- Registration Number
- NCT00386607
- Locations
- 🇳🇱
Investigative Centers, Netherlands, Netherlands
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 901
- Registration Number
- NCT00368277
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
- Conditions
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 768
- Registration Number
- NCT00344110
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.